Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.30 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10473323 | 0.83 | PKM (0.35) | PKMNPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL14616633 | 0.80 | KDM4E (0.37) | PKMALDH1A1SMN1; SMN2MAPTCYP1A2 | |
| SCHEMBL25320046 | 0.78 | MAPT (0.46) | PKMNPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL3436871 | 0.76 | PKM (0.45) | PKMNPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL2611106 | 0.76 | PKM (0.45) | PKMNPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL2611143 | 0.76 | PKM (0.45) | PKMNPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL3410199 | 0.75 | PKM (0.45) | PKMNPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL25421142 | 0.74 | PKM (0.44) | PKMNPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL1012284 | 0.74 | PKM (0.44) | PKMNPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL25421838 | 0.74 | PKM (0.44) | PKMNPC1ALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113979944-B | Synthesis method of high-selectivity 1-methyl-3- (trifluoromethyl) -1H-pyrazol-5-ol | 杭州欧晨科技有限公司 | 2023-08-22 | — | — | CN | claimed |
| US-4855442-A | Substituted 3-hydroxy pyrazoles | MONSANTO COMPANY (US) | 1989-08-08 | — | — | US | claimed |
| US-12622917-B2 | High-activity Wnt pathway inhibitor compound | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2026-05-12 | — | — | US | disclosed |
| EP-4551570-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Dong-A ST Co., Ltd. (KR) | 2025-05-14 | — | — | EP | disclosed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| CN-119403798-A | Novel compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | 东亚ST 株式会社 | 2025-02-07 | — | — | CN | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
| WO-2024009215-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-11 | — | — | WO | disclosed |
| US-20230390301-A1 | HIGH-ACTIVITY WNT PATHWAY INHIBITOR COMPOUND | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2023-12-07 | — | — | US | disclosed |
| CN-117088877-A | High-activity Wnt pathway inhibitor compound | 杭州阿诺生物医药科技有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230295220-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-09-21 | — | — | US | disclosed |
| US-5045106-A | 3-phenoxypyrazole | MONSANTO COMPANY (US) | 1991-09-03 | — | — | US | disclosed |
| EP-0442654-A2 | Heterocyclic compounds | ZENECA LIMITED (GB) | 1991-08-21 | — | — | EP | disclosed |
| US-4964895-A | Substituted 4-(4-nitrophenoxy) pyrazoles and their use as herbicides | MONSANTO COMPANY (US) | 1990-10-23 | — | — | US | disclosed |
| US-4948902-A | Process for making substituted pyrazoles | MONSANTO COMPANY (US) | 1990-08-14 | — | — | US | disclosed |
| EP-0371947-A1 | Substituted pyrazoles and their use as herbicides | Monsanto Company (US) | 1990-06-06 | — | — | EP | disclosed |
| EP-0370990-A1 | Herbicidal substituted pyrazoles | MONSANTO COMPANY (US) | 1990-05-30 | — | — | EP | disclosed |
| US-4855442-A | Substituted 3-hydroxy pyrazoles | MONSANTO COMPANY (US) | 1989-08-08 | — | — | US | disclosed |
| CN-1033457-A | 3-(4-nitrophenoxy) pyrazoles that replaces and as the purposes of weedicide | MONSANTO CO (US) | 1989-06-21 | — | — | CN | disclosed |
| EP-0295233-A2 | Substituted 3-(4-nitrophenoxy)pyrazoles and their use as herbicides | Monsanto Company (US) | 1988-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622917-B2 | High-activity Wnt pathway inhibitor compound | WNT1, WNT3, WNT3A | PKM 4344/4885NPC1 559/4885ALDH1A1 2901/4885 |
| US-20230295220-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | IL17A, BET1, CD4 | PKM 4563/4885NPC1 864/4885ALDH1A1 2551/4885 |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | PKM 2061/4885NPC1 89/4885ALDH1A1 3927/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | PKM 2061/4885NPC1 89/4885ALDH1A1 3927/4885 |
| US-20230390301-A1 | HIGH-ACTIVITY WNT PATHWAY INHIBITOR COMPOUND | WNT1, WNT3A, CTNNB1 | PKM 4095/4885NPC1 1548/4885ALDH1A1 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.